BioSpace News Archive

Pulse™ platform receives 510(k) clearance addressing spine technology and clinical requirements across all spine procedures [27-July-2018] SAN DIEGO, July 27, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today a

2U, Inc. announced that its partner, the University of Southern California (USC) Division of Biokinesiology and Physical Therapy, has welcomed 48 students to DPT@USC, USC’s new Hybrid Doctor of Physical Therapy (DPT) program.

Dr. Muenzer to review MPS II biology, standard of care, and rationale for the development of SB-913, an investigational genome editing treatment

Great Place to Work and PEOPLE recognize Encompass Health Home Health & Hospice as one of the PEOPLE’s “50 Companies That Care.”

Physio-Control, now part of Stryker, today announced it has received premarket approval by the U.S. Food and Drug Administration (FDA) to continue to market and distribute its full line of LIFEPAK professional defibrillators in the U.S.

The National Council on Disability (NCD) - a nonpartisan, independent federal agency - applauds announcements of two groundbreaking measures on the 28th anniversary of the Americans with Disabilities Act being signed.

bluebird bio, Inc. (Nasdaq: BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share.

Company Plans to Expand Programs and Geographic Reach

Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the Marketing Authorization Application of HulioTM (Product Code: FKB327), the companies’ biosimilar to Humira® (adalimumab), for all indications.

Alnylam Pharmaceuticals, Inc. announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open.